We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck presented multiple studies over the weekend demonstrating positive results in metastatic non-small cell lung cancer with its Keytruda immunotherapy. Read More
Over 90 percent of clinical trials evaluating targeted cancer therapies or immunotherapies fell short in reporting adverse events in their publications — specifically in reporting recurrent or late toxicities, and detailing the duration of adverse events — according to researchers who studied 81 trials related to FDA-approved solid tumor treatments. Read More
The Pancreatic Cancer Action Network is planning an adaptive clinical trial that will use genomic profiling to assign individual patients different treatment options. Read More
In a Phase III trial, Janssen’s injectable plaque psoriasis treatment delivered better head-to-head clinical results than international top-selling drug Humira, which amassed over $14 billion in sales in 2015. Read More
Repatha demonstrated positive effects on plaque buildup in coronary artery disease in patients already treated with optimized statin therapy. Read More